ClinicalTrials.gg
Not yet recruitingNCT07746154NeurofeedbackUpdated Nov 16, 2026

Alpha Down Electroencephalography (EEG) Neurofeedback for Alcohol Use Disorder: Feasibility Trial

An interventional study of EEG Neurofeedback in Alcohol Use Disorder (AUD), sponsored by Brigham and Women's Hospital. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Basic science

How we know

Updated Oct 1, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This pilot study is testing a short brain training program called neurofeedback in adults with alcohol use disorder. Participants will complete three sessions over about one week. The goal is to learn if this approach is easy to complete, well tolerated, and acceptable to participants. We will also explore whether it is associated with changes in alcohol cravings and drinking.

Read the detailed description

Alcohol use disorder (AUD) is a common condition, and many individuals do not respond fully to existing treatments. Neurofeedback is a non-invasive method that uses real-time electroencephalography (EEG) signals to provide feedback, allowing individuals to learn to modulate their brain activity.

This pilot study will evaluate a brief EEG-based neurofeedback intervention in adults with AUD. Participants will complete three in-person sessions over approximately one week. During each session, EEG sensors are placed on the scalp to measure brain activity, and participants receive real-time feedback based on these signals.

The neurofeedback protocol targets downregulation of alpha-band activity (8-12 Hz). This approach differs from traditional alpha-theta neurofeedback and is intended to target patterns of brain activity related to attention, inhibitory control, and craving.

The primary aim is to assess feasibility, tolerability, and acceptability. Feasibility will be evaluated through recruitment, retention, and session completion. Tolerability will be assessed by monitoring adverse events, and acceptability will be assessed through participant-reported experience.

Exploratory outcomes will include changes in alcohol craving and alcohol use based on self-report measures. These analyses are exploratory and intended to inform future studies.

02

Conditions studied

  • Alcohol Use Disorder (AUD)

Browse trials for

Keywords

  • Alcohol Use Disorder
  • EEG neurofeedback
03

In context

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

This study's planned enrollment of 10 is below the median of 88 across 1,433 interventional studies indexed under Alcoholism.

Browse Alcoholism studies →

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.

Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ages 18-65
  • Meets criteria for current Alcohol Use Disorder
  • Willing and able to provide
  • Alcohol consumption within the past 30 days
  • Not requiring inpatient withdrawal management at the time of enrollment

Exclusion criteria

Exclusion Criteria:

  • History of epilepsy or seizure disorder (excluding uncomplicated alcohol withdrawal seizures)
  • Current psychosis, mania, or acute suicidality, or any psychiatric condition that would impair the ability to provide or safely participate
  • Acute alcohol intoxication at the time of study visits, as determined by -breathalyzer
  • Pregnancy or breastfeeding
  • Implanted electronic medical devices or metal in the head (excluding dental work), if incompatible with electroencephalography (EEG) procedures
  • Severe cognitive impairment interfering with informed consent or participation
  • Any medical or psychiatric condition that, in the opinion of the investigators, would make participation unsafe or interfere with study procedures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Neurofeedback

    Device: EEG Neurofeedback

Interventions

  • DeviceEEG Neurofeedback

    Participants will receive a brief course of EEG-based neurofeedback consisting of three sessions over approximately one week. During each session, scalp electrodes are placed to record brain activity using electroencephalography (EEG). Real-time feedback is provided to guide participants in modulating their brain activity. The neurofeedback protocol targets downregulation of alpha-band activity (8-12 Hz). Training is delivered using a standardized protocol with real-time visual and/or auditory feedback. Each session lasts approximately 20 minutes, with additional time for setup and brief assessments.

06

What researchers measure

Primary outcomes

  1. Participant retention rate over 1 week

    Proportion of participants who complete all study visits

    Time frame: one week

  2. Proportion of participants experiencing adverse events during neurofeedback sessions over 1 week

    Number and severity of adverse events

    Time frame: One week

  3. Proportion of scheduled neurofeedback sessions completed over 1 week

    Proportion of scheduled neurofeedback sessions completed

    Time frame: One week

Secondary outcomes

  1. Change in alcohol craving (Penn Alcohol Craving Scale [PACS] total score) from baseline to Visit 3 (~1 week)

    Alcohol craving will be assessed using the Penn Alcohol Craving Scale (PACS). PACS total scores range from 0 to 30, with higher scores indicating greater alcohol craving. Change in PACS total score from baseline to Visit 3 (\~1 week) will be analyzed.

    Time frame: One week

  2. Change in alcohol consumption measured by Timeline Follow-Back (TLFB) from baseline (Visit 1) to post-intervention (Visit 3, ~1 week)

    Alcohol consumption will be assessed using the Timeline Follow-Back (TLFB) method. Change in number of standard drinks over the assessment period from baseline to the final visit will be analyzed.

    Time frame: One week

  3. Change in Alpha Power During Neurofeedback Training Relative to Pre-Training Resting EEG

    Change in absolute EEG alpha-band power (8-12 Hz) at Pz during neurofeedback training compared with the 3-minute pre-training eyes-open resting EEG recording. Alpha power will be assessed during each of the three neurofeedback sessions to characterize alpha suppression during training.

    Time frame: During each of the three neurofeedback sessions over approximately 1 week.

  4. Post-Training Alpha Rebound

    Change in absolute EEG alpha-band power (8-12 Hz) at Pz between 3-minute eyes-open resting EEG recordings obtained immediately before and after each neurofeedback session. An increase in post-training resting alpha power relative to pre-training is considered evidence consistent with alpha rebound. Relative alpha power will also be explored.

    Time frame: Immediately before and after each of the three neurofeedback sessions over approximately 1 week.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Imperatori C, Della Marca G, Amoroso N, Maestoso G, Valenti EM, Massullo C, Carbone GA, Contardi A, Farina B. Alpha/Theta Neurofeedback Increases Mentalization and Default Mode Network Connectivity in a Non-Clinical Sample. Brain Topogr. 2017 Nov;30(6):822-831. doi: 10.1007/s10548-017-0593-8. Epub 2017 Sep 21. PubMed 28936792 ↗
  • Wan H, Chen B, Li X, Bu J. Effect of EEG neurofeedback therapy on addiction disorders: A systematic review and meta-analysis. Addiction. 2026 Feb;121(2):225-238. doi: 10.1111/add.70164. Epub 2025 Aug 12. PubMed 40798852 ↗
  • Affan RO, Huang S, Cruz SM, Holcomb LA, Nguyen E, Marinkovic K. High-intensity binge drinking is associated with alterations in spontaneous neural oscillations in young adults. Alcohol. 2018 Aug;70:51-60. doi: 10.1016/j.alcohol.2018.01.002. Epub 2018 Jan 8. PubMed 29778070 ↗

Individual participant data

Plan to share: No — There is no current plan to make de-identified individual participant data collected in this study available to researchers outside the study team.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 12 months is below that.

Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start Aug 2026 → Dec 2026 and primary completion Jul 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2026
First posted
Aug 4, 2026
StartEst.
Dec 1, 2026was Aug 2026
Primary completionEst.
Dec 1, 2027was Jul 2027
CompletionEst.
Feb 1, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Dec 1, 2026
Oct 1, 2026
Primary completion
Jul 1, 2027→Dec 1, 2027
Oct 1, 2026
Eligibility
5 inclusion criteria added, 1 removed; 7 exclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedAdults ages 18-65 Meets DSM-5 criteria for current Alcohol Use Disorder Willing and able to provide informed consent Participants must report alcohol consumption within the past 30 days. Not requiring inpatient withdrawal management at the time of enrollment
  • AddedAdults ages 18-65
  • AddedMeets DSM-5 criteria for current Alcohol Use Disorder
  • AddedWilling and able to provide informed consent
  • AddedAlcohol consumption within the past 30 days
  • AddedNot requiring inpatient withdrawal management at the time of enrollment
Exclusion criteria
  • RemovedHistory of epilepsy or seizure disorder (excluding uncomplicated alcohol withdrawal seizures) Current psychosis, mania, or acute suicidality, or any psychiatric condition that would impair the ability to provide informed consent or safely participate Acute alcohol intoxication at the time of study visits (as determined by breathalyzer) Pregnancy or breastfeeding Implanted electronic medical devices or metal in the head (excluding dental work), if incompatible with EEG procedures Severe cognitive impairment interfering with informed consent or participation Any medical or psychiatric condition that, in the opinion of the investigators, would make participation unsafe or interfere with study procedures
  • AddedHistory of epilepsy or seizure disorder (excluding uncomplicated alcohol withdrawal seizures)
  • AddedCurrent psychosis, mania, or acute suicidality, or any psychiatric condition that would impair the ability to provide informed consent or safely participate
  • AddedAcute alcohol intoxication at the time of study visits, as determined by -breathalyzer
  • AddedPregnancy or breastfeeding
  • AddedImplanted electronic medical devices or metal in the head (excluding dental work), if incompatible with electroencephalography (EEG) procedures
  • AddedSevere cognitive impairment interfering with informed consent or participation
  • AddedAny medical or psychiatric condition that, in the opinion of the investigators, would make participation unsafe or interfere with study procedures
Oct 1, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 1, 2026
  • EditedChange in alcohol craving (Penn Alcohol Craving Scale [PACS] total score) from baseline to Visit 3 (~1 week)Time frame: One week
What changed on Nov 16, 2026
  • AddedChange in Alpha Power During Neurofeedback Training Relative to Pre-Training Resting EEGTime frame: During each of the three neurofeedback sessions over approximately 1 week.
  • AddedPost-Training Alpha ReboundTime frame: Immediately before and after each of the three neurofeedback sessions over approximately 1 week.
across 2 updates, Oct 1, 2026 – Nov 16, 2026
Title
Alpha Down Electroencephalography (EEG) Neurofeedback for Alcohol Use Disorder: Feasibility Trial
Oct 1, 2026
Show all 2 updates
  1. Nov 16, 2026
    Secondary outcomes 2 added
    What changed in the outcomes
    • AddedChange in Alpha Power During Neurofeedback Training Relative to Pre-Training Resting EEGTime frame: During each of the three neurofeedback sessions over approximately 1 week.
    • AddedPost-Training Alpha ReboundTime frame: Immediately before and after each of the three neurofeedback sessions over approximately 1 week.
    + 1 other change: verification date
  2. Oct 1, 2026
    Start date Aug 1, 2026→Dec 1, 2026
    Primary completion Jul 1, 2027→Dec 1, 2027
    Eligibility 5 inclusion criteria added, 1 removed; 7 exclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedAdults ages 18-65 Meets DSM-5 criteria for current Alcohol Use Disorder Willing and able to provide informed consent Participants must report alcohol consumption within the past 30 days. Not requiring inpatient withdrawal management at the time of enrollment
    • AddedAdults ages 18-65
    • AddedMeets DSM-5 criteria for current Alcohol Use Disorder
    • AddedWilling and able to provide informed consent
    • AddedAlcohol consumption within the past 30 days
    • AddedNot requiring inpatient withdrawal management at the time of enrollment
    Exclusion criteria
    • RemovedHistory of epilepsy or seizure disorder (excluding uncomplicated alcohol withdrawal seizures) Current psychosis, mania, or acute suicidality, or any psychiatric condition that would impair the ability to provide informed consent or safely participate Acute alcohol intoxication at the time of study visits (as determined by breathalyzer) Pregnancy or breastfeeding Implanted electronic medical devices or metal in the head (excluding dental work), if incompatible with EEG procedures Severe cognitive impairment interfering with informed consent or participation Any medical or psychiatric condition that, in the opinion of the investigators, would make participation unsafe or interfere with study procedures
    • AddedHistory of epilepsy or seizure disorder (excluding uncomplicated alcohol withdrawal seizures)
    • AddedCurrent psychosis, mania, or acute suicidality, or any psychiatric condition that would impair the ability to provide informed consent or safely participate
    • AddedAcute alcohol intoxication at the time of study visits, as determined by -breathalyzer
    • AddedPregnancy or breastfeeding
    • AddedImplanted electronic medical devices or metal in the head (excluding dental work), if incompatible with electroencephalography (EEG) procedures
    • AddedSevere cognitive impairment interfering with informed consent or participation
    • AddedAny medical or psychiatric condition that, in the opinion of the investigators, would make participation unsafe or interfere with study procedures
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in alcohol craving (Penn Alcohol Craving Scale [PACS] total score) from baseline to Visit 3 (~1 week)Time frame: One week
    Title Alpha Down Electroencephalography (EEG) Neurofeedback for Alcohol Use Disorder: Feasibility Trial
    + 3 other changes: verification date, responsible party and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07746154
Responsible party
Olga Terechin, MD (Principal investigator, Associate Psychiatrist, Brigham and Women's Hospital) — Principal investigator
First posted
Aug 4, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Naomi Rosenblum
Contact
nrosenblum@bwh.harvard.edu
8572054415

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion